{
    "2021-07-19": [
        [
            {
                "time": "2021-07-19",
                "orginal_text": "A股资金流向（7月19日）：资金避高就低，医药、白酒龙头重获资金青睐",
                "features": {
                    "keywords": [
                        "医药",
                        "白酒",
                        "资金流向",
                        "避高就低"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "白酒"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "北向资金今日净买入近44亿元，持续加仓白酒、医药股",
                "features": {
                    "keywords": [
                        "北向资金",
                        "净买入",
                        "白酒",
                        "医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "白酒"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "艾德证券期货：复星医药股价创历史新高，“复必泰”有望加速落地？",
                "features": {
                    "keywords": [
                        "复星医药",
                        "股价新高",
                        "复必泰",
                        "加速落地"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "郭广昌继续重仓海南，400亿欲将海航收入囊中？",
                "features": {
                    "keywords": [
                        "郭广昌",
                        "重仓海南",
                        "海航",
                        "400亿"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "航空",
                        "地产"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "李浩德：复星医药近期五大利好盘点",
                "features": {
                    "keywords": [
                        "复星医药",
                        "利好",
                        "盘点"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "医药行业2021年中期投资策略：创新为行业发展主旋律 聚焦相关高景气、高尖端细分领域",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "创新",
                        "高景气",
                        "高尖端"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "复星医药董事长兼CEO吴以芳入选《福布斯2021中国最佳CEO榜》",
                "features": {
                    "keywords": [
                        "复星医药",
                        "吴以芳",
                        "福布斯",
                        "最佳CEO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "【异动股】复星医药(02196.HK)涨4.1%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "异动股",
                        "涨4.1%"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-07-19",
                "orginal_text": "康泰生物布局mRNA人用传染病疫苗项目",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "mRNA",
                        "疫苗",
                        "项目"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}